Scholar Rock Holding Earnings Call Transcripts
Fiscal Year 2026
-
Apitegromab’s BLA has been resubmitted to the FDA with two fill-finish facilities, offering dual paths to approval and robust supply chain flexibility. Launch preparations are advanced, with sufficient inventory and payer engagement underway. EMA review is on track for mid-2026.
-
The company is preparing for U.S. and European launches of its first-in-class myostatin inhibitor for SMA, supported by strong clinical data and a robust financial position. Regulatory delays are being addressed, with commercial and pipeline expansion plans advancing globally.
-
Apitegromab's approval was delayed due to manufacturing compliance, but remediation and regulatory engagement are progressing, with a 2026 U.S. launch targeted. Commercial and supply chain readiness are strong, global expansion is planned, and financial resources are robust.
-
Apitegromab is positioned for U.S. and European launches in 2026, pending resolution of manufacturing compliance at the Indiana facility and validation of a second site. Robust demand and a multi-billion dollar opportunity are anticipated, with pipeline expansion into FSHD and other neuromuscular diseases underway.
-
Apitegromab is set for U.S. and European launches in 2026 after strong phase III results in SMA, with expansion into FSHD and other neuromuscular diseases planned. The company is financially positioned for growth, with a $2B+ market opportunity and global commercialization strategy.
Fiscal Year 2025
-
Apitegromab is on track for U.S. and EU launches in 2026, pending regulatory approvals, with strong commercial and supply chain preparations underway. Financially, the company ended 2025 with $368M in cash and secured a $550M debt facility to support launch and pipeline advancement.
-
Significant transformation in 2025 included positive Phase 3 results for apitegromab in SMA, a BLA filing, and leadership changes. Regulatory delays due to manufacturing issues shifted the anticipated U.S. launch to 2026, allowing more time for commercial preparation and global expansion.
-
Apitegromab is poised to become the first muscle-targeted therapy for SMA, with strong phase III data supporting its use alongside existing SMN therapies. Regulatory approval is delayed due to manufacturing issues, but launch is expected in 2026, supported by a robust financial position and plans for global expansion.
-
Apitegromab's approval is delayed due to manufacturing compliance issues, but remediation is nearly complete and FDA reinspection is expected in early 2025. Commercial launch plans target SMA patients on existing therapies, with global expansion and a strong financial runway into 2027.
-
Apitegromab's U.S. approval was delayed due to manufacturing compliance, not efficacy. The company expects to resubmit its BLA after facility remediation, with a 2026 launch targeted. Financials remain strong, with a cash runway into 2027 and strategic investments prioritized.
-
Apitegromab is on track for U.S. launch in Q3 2025 pending FDA approval, with European expansion planned for 2026. Financial position is strong with a cash runway into 2027, and commercial teams are fully prepared. Regulatory and manufacturing risks are being actively managed.
-
The phase 2 Embraze trial met its primary endpoint, showing Apitegromab plus Tirzepatide significantly preserved lean mass in adults with obesity, with no compromise in fat or overall weight loss and an encouraging safety profile. Focus remains on neuromuscular indications, with future data and next-generation candidates in development.
-
Leadership is focused on global commercialization of apitegromab for SMA, with robust clinical data supporting a broad label and durable benefits. Expansion into other rare neuromuscular disorders and a cautious approach to obesity trials are planned, supported by a strong cash position and disciplined investment.
-
A new leadership team with deep biotech experience is preparing for the global launch of apitegromab, with key phase II obesity data due in June and a PDUFA date in September. Regulatory review is progressing smoothly, and the company anticipates broad SMA label coverage and steady commercial uptake.
-
Q1 2025 saw strong progress with positive phase 3 results for apitegromab in SMA, FDA priority review, and commercial launch preparations underway. Financial position remains robust with $364.4M in cash and additional debt capacity, supporting a runway into 2027.
-
Apitegromab is under FDA review for SMA, with a broad label expected and a focus on patients aged two and above. Phase 3 data show meaningful functional gains and a strong safety profile. The company is preparing for commercial launch and expanding its pipeline into cardiometabolic and neuromuscular diseases.
-
Momentum continues into 2025 with apitegromab poised for commercial launch in SMA, supported by strong phase 3 data and a projected $2B+ global opportunity. Expansion into new neuromuscular and cardiometabolic indications is underway, with key clinical and regulatory milestones expected this year.
Fiscal Year 2024
-
Pivotal SAPPHIRE results support apitegromab's potential as the first muscle-targeted SMA therapy, with regulatory filings on track and a U.S. launch planned for Q4 2025. Cardiometabolic pipeline advances with EMBRAZE data expected in Q2 and SRK-439 IND in Q3, amid strong commercial preparations.
-
Phase III data showed significant functional gains and a strong safety profile for apitegromab in SMA, with high patient and advocacy support. Commercial launch preparations are advanced, targeting 2025, and pipeline expansion into obesity and cardiometabolic disease is underway.
-
Apitegromab’s phase III trial in SMA showed significant functional improvement and a strong safety profile, with regulatory filings planned for Q1 and potential approval by year-end. The company targets a $1B+ market opportunity, plans independent U.S. commercialization, and is expanding into obesity with phase II data expected in Q2.
-
Positive phase 3 SAPPHIRE results for apitegromab in SMA support regulatory filings in early 2025, with a strong cash position of $463 million enabling commercial launch preparations and pipeline expansion. SRK-439 advances in obesity, with key data readouts expected in 2025.
-
The pivotal phase III SAPPHIRE trial showed that apitegromab plus standard of care led to significant and consistent motor function improvements in SMA patients aged 2–21, with a favorable safety profile and no new safety signals. Regulatory submissions are planned for early 2025.
-
Major SMA and obesity clinical milestones are expected in the next 6–12 months, with SAPPHIRE data in Q4 and EMBRACE obesity results in Q2 2025. Scholar Rock's selective myostatin approach differentiates its pipeline, with global commercialization and partnership strategies in place.
-
Key milestones met in H1 2024, with pivotal SAPPHIRE Phase 3 SMA data expected in Q4 and EMBRACE obesity study top-line results in Q2 2025. Long-term apitegromab data show sustained benefit and safety, while pipeline advances in obesity, oncology, and fibrosis continue.
-
A highly selective approach to TGF-β biology is driving a robust pipeline in SMA and obesity, with apitegromab showing strong efficacy and safety in SMA and SRK-439 targeting muscle preservation in weight loss. Key clinical readouts and a commercial launch are expected within 12-24 months.
-
Major SMA Phase III data is expected in Q4, with a concurrent obesity proof-of-concept trial underway to demonstrate muscle preservation with GLP-1 therapies. SRK-439 is advancing for broader cardiometabolic use, and the company is well-funded into late 2025, exploring partnerships for its oncology assets.
-
SRK-181 combined with pembrolizumab demonstrated promising antitumor activity and durability, especially in biomarker-selected ccRCC patients, with a manageable safety profile. Biomarker-driven strategies could double response rates, and regulatory discussions are planned for Q3 to define next development steps.